SRRK Live signals | Maximize Profits with Getagraph.com

SELL 92473 min ago

@ $15.49

Issued: 14 Feb 2024 @ 15:23

Return: -9.94%

Previous signal: Feb 14 - 12:00

Previous signal: Buy

Return: 1.51 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	668 939
Average Volume	793 225
Market Cap	1.09B
EPS	$-0.460 ( 2024-03-19 )
Next earnings date	( $-0.490 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.01
ATR14	$0.0170 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Peng Katie	Buy	35 767	Stock Option (Right to Buy)
2024-04-09	Peng Katie	Buy	26 825	Common Stock
2024-02-16	Myles Edward H	Sell	4 744	Common Stock
2024-02-16	Qatanani Mo	Sell	2 512	Common Stock
2024-02-16	Parlavecchio Caryn	Sell	3 751	Common Stock

INSIDER POWER
57.36
Last 96 transactions
Buy: 9 442 259 \| Sell: 2 434 527

Volume Correlation

Long: 0.21 (neutral)

Short: -0.92 (very strong negative)

Signal:(32.648) Neutral

Scholar Rock Holding Corp Correlation

10 Most Positive Correlations
FOX	0.897
FOXA	0.891
CRTO	0.889
BPRN	0.882
DSKE	0.872
IMAB	0.872
CIGI	0.867
CINF	0.86
CVCY	0.86
FCNCP	0.847

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Scholar Rock Holding Corp Correlation - Currency/Commodity

0.46
( neutral )

-0.06
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.05
( neutral )

-0.30
( neutral )

Scholar Rock Holding Corp Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.84M (0.00 %)
EPS:	$-1.990

Q4	2023
Revenue:	$0
Gross Profit:	$-672 000 (0.00 %)
EPS:	$-0.610

Q3	2023
Revenue:	$0
Gross Profit:	$-708 000 (0.00 %)
EPS:	$-0.530

Q2	2023
Revenue:	$0
Gross Profit:	$-2.58M (0.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.